Response Genetics, Inc. (NASDAQ: RGDX) will announce first quarter 2008
financial results in a press release Thursday, May 15 after close of
market.
Response Genetics, Inc. also announced today that Kathleen Danenberg
President and CEO of Response Genetics, Inc., will present at the Rodman
& Renshaw Fifth Annual Global Healthcare Conference at 5:15 p.m. CET /
11:15 a.m. ET / 8:15 a.m. PT on Monday, May 19. The conference is being
held at Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco.
The presentation will be made available by webcast and can be accessed
at www.responsegenetics.com.
About Response Genetics, Inc.
Response Genetics, Inc. ("RGI") (the "Company")
(NASDAQ: RGDX) is engaged in the research and development of
pharmacogenomic cancer diagnostic tests based on its proprietary and
patented technologies. RGI´s technologies enable extraction and analysis
of genetic information from genes derived from tumor samples stored as
formalin-fixed and paraffin embedded specimens. RGI currently generates
revenue primarily from the sales of its proprietary analytical
pharmacogenomic testing services of clinical trial specimens to the
pharmaceutical industry. The Company was founded in 1999 and its
principal headquarters are located in Los Angeles, California. For more
information, please visit www.responsegenetics.com.
Forward Looking Statement Notice
Except for the historical information contained herein, this press
release and the statements of representatives of RGI related thereto
contain or may contain, among other things, certain forward-looking
statements, within the meaning of the Private Securities Litigation
Reform Act of 1995.
Such forward-looking statements involve significant risks and
uncertainties. Such statements may include, without limitation
statements with respect to the Company´s plans, objectives, projections
expectations and intentions, such as the ability of the Company to
analyze cancer samples, the potential for using the results of this
research to develop diagnostic tests for cancer, the usefulness of
genetic information to tailor treatment to patients, the ability of the
Company to make its ResponseDx:LungTM and
ResponseDX:ColonTM tests available in a number
of institutions, and other statements identified by words such as
"projects," "may," "could," "would," "should," "believes," "expects,"
"anticipates," "estimates," "intends," "plans" or similar expressions.
These statements are based upon the current beliefs and expectations of
the Company´s management and are subject to significant risks and
uncertainties, including those detailed in the Company´s filings with
the Securities and Exchange Commission. Actual results, including
without limitation, actual sales results, if any, or the application of
funds, may differ from those set forth in the forward-looking
statements. These forward-looking statements involve certain risks and
uncertainties that are subject to change based on various factors (many
of which are beyond the Company´s control). The Company undertakes no
obligation to publicly update forward-looking statements, whether
because of new information, future events or otherwise, except as
required by law.
